Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...

Psychedelic Leader to Advance Mental Health in 2021 with Growth of Clinics, Lab and Partnerships

(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...

The Psychedelic Opportunity You Need to Know About

When Stockhouse Editorial last caught up with Toronto-based CYBIN Inc. ( N.CYBN , OTC: CYBN , Forum ) back in September 2020 , the psychedelic life sciences company was just going public…and to much fanfare. Cybin is a life sciences company that views psychedelic subst...

The Company That’s Delivering Safe, Evidence-Based Psychedelic-Assisted Psychotherapies

(Click image to play podcast) Stockhouse investors who are dialed into the not-only nascent but now, pardon the pun, mushrooming psychedelics sector are likely familiar with a mental health and wellness company “centred on developing and supporting the safe, ev...

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...

Unlocking the Healing Potential of Safe, Natural Psychedelics

When we last caught up with Filament Health Corp. ( NEO.FH , Forum ) and their CEO and Co-Founder, Ben Lightburn last July , our Stockhouse investors were introduced to an industry leader in exclusively-natural psychedelic drug discovery and extraction. The company enga...